Literature DB >> 15235055

Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure.

Shu Kasama1, Takuji Toyama, Hisao Kumakura, Yoshiaki Takayama, Takehiro Ishikawa, Shuichi Ichikawa, Tadashi Suzuki, Masahiko Kurabayashi.   

Abstract

UNLABELLED: The activation of the renin-angiotensin-aldosterone system (RAAS) prevents the uptake of norepinephrine in the myocardium. Atrial natriuretic peptide (ANP), a circulating hormone of cardiac origin, has vasodilatory and diuretic properties and can inhibit the RAAS. However, its effect on cardiac sympathetic nerve activity has not been determined.
METHODS: We studied 58 patients with decompensated nonischemic acute heart failure who were treated with intravenous low-dose dopamine and diuretics. Twenty-nine patients (group A) were assigned to also receive intravenous ANP, whereas the remaining 29 patients (group B) continued their established drug regimen. The dopamine or ANP was continuously infused for >96 h. The left ventricular end-diastolic volume and ejection fraction were determined by echocardiography before and 4 wk after treatment. The delayed heart-to-mediastinum (H/M) count ratio, delayed total defect score, and washout rate were determined from (123)I-metaiodobenzylguanidine (MIBG) images 3 wk after treatment.
RESULTS: Fifty-six patients enrolled in the trial completed the entire protocol. After treatment of group A (n = 28), the left ventricular end-diastolic volume decreased from 186 +/- 42 to 174 +/- 48 mL (P < 0.05), and left ventricular ejection fraction increased from 32% +/- 9% to 36% +/- 7% (P < 0.05). In group B (n = 28), these parameters did not change significantly. In addition, 3 wk after treatment of group A, the total defect score was significantly lower (30 +/- 9 vs. 38 +/- 9, P < 0.01), the H/M count ratio was significantly higher (1.86 +/- 0.21 vs. 1.62 +/- 0.23, P = 0.0001), and washout rate was significantly lower (42% +/- 12% vs. 49% +/- 12%, P < 0.05) than in group B.
CONCLUSION: The present study demonstrates an improvement in echocardiographic parameters with ANP infusion. In addition, cardiac (123)I-MIBG scintigraphic parameters were better in patients who received ANP infusion along with dopamine and diuretics than in patients who received standard conventional therapy. These findings indicate that intravenous administration of ANP can benefit cardiac sympathetic nerve activity and improve left ventricular remodeling in patients with acute heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235055

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

2.  Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

3.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Tomoaki Nakata; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

Review 4.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

5.  Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

6.  Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-01       Impact factor: 9.236

Review 7.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

8.  ANP is cleared much faster than BNP in patients with congestive heart failure.

Authors:  Kuniko Kimura; Yukinari Yamaguchi; Manabu Horii; Hiroyuki Kawata; Hiromitsu Yamamoto; Shiro Uemura; Yoshihiko Saito
Journal:  Eur J Clin Pharmacol       Date:  2007-05-04       Impact factor: 2.953

Review 9.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

10.  Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model.

Authors:  Ryuta Imaki; Shinichi Niwano; Hiroe Niwano; Daisuke Satoh; Toru Yoshida; Yoshihiko Masaki; Tohru Izumi
Journal:  Indian Pacing Electrophysiol J       Date:  2008-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.